title: Romidepsin for cutaneous T-cell lymphoma.
abstract: Cutaneous T-cell lymphomas are relatively rare lymphomas and the most common form is mycosis fungoides. Its rare leukemic variant is Sezary syndrome. Advanced-stage disease is typically treated with bexarotene (a retinoid), IFN-α or conventional chemotherapeutic agents, but relapses are inevitable. Histone deacetylase inhibitors that modify the epigenome are an attractive addition to the armamentarium. Based on two large Phase II studies, the US FDA approved intravenous romidepsin for patients with relapsed/refractory cutaneous T-cell lymphomas. Romidepsin provides a subset of patients with an opportunity for prolonged clinical responses with a tolerable side-effect profile.
authors.affiliation: Department of Haematology, Peter MacCallum Cancer Centre, Division Cancer Medicine, St Andrew's Place, East Melbourne, Australia.
authors.forename: H Miles
authors.initials: HM
authors.lastname: Prince
authors.forename: Michael
authors.initials: M
authors.lastname: Dickinson
authors.forename: Amit
authors.initials: A
authors.lastname: Khot
mesh_terms: D017322:Clinical Trials, Phase II as Topic; D047630:Depsipeptides / Q000008:administration & dosage*; D004341:Drug Evaluation; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D047630:Depsipeptides; D056572:Histone Deacetylase Inhibitors; C087123:romidepsin